Prognostic factors for patients undergoing surgery for femur metastases following systemic treatment

Table 1 Patient clinical characteristics

Characteristic	n
Age at bone metastasis diagnosis	Median 73.5 (range, 50-87)
Sex
Male	11
Female	13
Type of cancer
Lung cancer
With molecularly targeted therapy	1
Without molecularly targeted therapy	3
Breast cancer
Hormone dependent	5
Hormone independent	2
Prostate cancer
Hormone dependent	2
Hormone independent	1
Colorectal cancer	2
Esophageal cancer	1
Hepatocellular carcinoma	1
Kidney cancer	1
Bladder cancer	1
Multiple myeloma	3
Malignant lymphoma	1
Surgical method
Osteosynthesis	17
Artificial head replacement	7
Systemic treatment before surgery
Hormone therapy	6
Anticancer drugs and/or molecularly targeted drugs	18
Visceral metastasis
Yes	14
No	10
Number of bone metastases
1	6
Multiple	18
Pathological fractures
Yes	6
No	18
Systemic treatment after surgery
Yes	14
No	10

Table 2 Univariate analysis of the overall survival

Characteristics	n	Median OS	95%CI	P value
Age				0.19
> 70	15	5	1-15
< 71	9	10	4 to not censored
Sex				0.67
Male	11	6	2-15
Female	13	7	1 to not censored
Type of cancer				0.020
Low growth	11	29	1 to not censored
Moderate or rapid growth	13	6	2-9
Surgical method				0.0040
Osteosynthesis	17	6	1-9
Artificial head replacement	7	77	4 to not censored
Type of systemic treatment before surgery				0.064
Hormone therapy	6	29	1 to not censored
Anticancer drugs and/or molecularly targeted drugs	18	5	3-9-not censored
Visceral metastasis				0.017
Yes	14	6	1-7
No	10	15	1 to not censored
Number of bone metastases				0.94
1	6	9	1 to not censored
Multiple	18	6	4-29
Pathological fractures				0.153
Yes	6	9	4 to not censored
No	18	6	2-15
Systemic treatment after surgery				0.0030
Yes	14	29	5 to not censored
No	10	4	1-6
Albumin				0.057
≥ 3.7	13	15	3 to not censored
< 3.7	11	6	1-7
CRP				0.867
> 0.4	16	7	4-29
≤ 0.4	8	5	1 to not censored
LDH				0.58
≥ 250	11	6	1-28
< 250	13	7	3 to not censored

OS: Overall survival; CI: Confidence interval; CRP: C-reactive protein; LDH: Lactate dehydrogenase.

Table 3 Multivariate analysis of the overall survival

Characteristics		HR	95%CI	P value
Systemic treatment after the surgery	Yes	0.27	0.085-0.85	0.025
Visceral metastasis	No	0.35	0.11-1.1	0.080

HR: Hazard ratio; CI: Confidence interval.